Lilly to participate in TD Cowen's 46th Annual Health Care Conference
Rhea-AI Summary
Eli Lilly and Company (NYSE:LLY) will participate in TD Cowen's 46th Annual Health Care Conference on March 2, 2026. Lucas Montarce, executive vice president and chief financial officer, will appear in a fireside chat at 3:10 p.m. ET.
A live audio webcast will be available via Lilly's investor site under Webcasts & Presentations, with a replay accessible on the same site for approximately 90 days.
Positive
- None.
Negative
- None.
News Market Reaction – LLY
On the day this news was published, LLY declined 0.38%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peers show mixed moves: ABBV +1.35%, NVS +0.58%, NVO +0.55% versus JNJ -0.47% and AZN -0.04%, indicating stock-specific factors rather than a unified sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 09 | Acquisition announcement | Positive | -1.3% | Agreement to acquire Orna Therapeutics for up to $2.4B in cash. |
| Feb 04 | Earnings and guidance | Positive | +10.3% | Q4 2025 results and 2026 guidance with strong revenue and EPS outlook. |
| Jan 30 | Capacity expansion | Positive | +1.3% | More than $3.5B commitment to new injectable medicine facility. |
| Jan 21 | Earnings call date | Neutral | +3.6% | Set date and webcast details for Q4 2025 results call. |
| Jan 20 | Regulatory milestone | Positive | +0.3% | FDA Breakthrough Therapy designation for sofetabart mipitecan in ovarian cancer. |
Recent news has largely been positive (acquisition, major investment, FDA designation, strong earnings), with mostly positive or modest price reactions and one acquisition-related divergence.
Over recent months, Eli Lilly reported strong Q4 2025 results with revenue of $19.3B and 2026 guidance of $80–$83B, announced a more than $3.5B manufacturing facility in Pennsylvania, and received FDA Breakthrough Therapy designation for sofetabart mipitecan. It also agreed to acquire Orna Therapeutics for up to $2.4B. Against this backdrop of sizable strategic and regulatory milestones, today’s TD Cowen conference participation fits as ongoing investor engagement rather than a new fundamental catalyst.
Market Pulse Summary
This announcement highlights Eli Lilly’s participation in TD Cowen’s 46th Annual Health Care Conference, with a 3:10 p.m. Eastern fireside chat and a webcast replay available for 90 days. Set against recent major events—earnings, an acquisition agreement, FDA Breakthrough Therapy designation, and large manufacturing investments—the news primarily reflects ongoing investor engagement. Observers may focus on whether commentary at the conference elaborates on prior guidance, pipeline milestones, and capital deployment plans.
AI-generated analysis. Not financial advice.
A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly's investor website at https://investor.lilly.com/webcasts-and-presentations. A replay of the presentation will be available on this same website for approximately 90 days.
About Lilly
Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram, and LinkedIn. F-LLY
Trademarks and Trade Names
All trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are references in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.
Refer to: | Ashley Hennessey; gentry_ashley_jo@lilly.com; 317-416-4363 (Media) |
Michael Czapar; czapar_michael_c@lilly.com; 317-617-0983 (Investors) |
View original content to download multimedia:https://www.prnewswire.com/news-releases/lilly-to-participate-in-td-cowens-46th-annual-health-care-conference-302687791.html
SOURCE Eli Lilly and Company
FAQ
When will Eli Lilly (LLY) present at TD Cowen's 46th Annual Health Care Conference?
Who will represent Eli Lilly (LLY) at the TD Cowen conference on March 2, 2026?
How can investors watch the Lilly (LLY) webcast from TD Cowen's March 2, 2026 conference?
Will a replay of Eli Lilly's (LLY) TD Cowen presentation be available after March 2, 2026?
What time is the Lilly (LLY) fireside chat at TD Cowen's 46th Annual Health Care Conference?
